Ann: Rett Syndrome Phase I/II trial shows significant benefits, page-10

With a bit of help from somebody smarter than I am - looked at the FDA clinical review from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217026Orig1s000MedR.pdf

So the RSBQ data is similar - but NTI had a far greater effect - especially on mood, but ovbviously a much smaller sample size of 14 comparing with baseline, v Daybue with 82 subjects, and comparing to placebo.
Overall cannot say that this is unimportant, when the magnitude is taken into account. So now I actually will be changing my tune, to become more positive about this treatment for Rett.

I'm not sure why management haven't quoted this Daybue data in presentations. Maybe I missed it?

Daybue:

NTI164